Reversal of the antiaggregant effect of ticagrelor in combination with acetylsalicylic acid, using normal platelets

Paul Kruger

doi:10.26182/5e8a796c6e24c

Reversal of the antiaggregant effect of ticagrelor in combination with acetylsalicylic acid, using normal platelets

Paul Kruger

UWA Medical School

Research output: Thesis › Master's Thesis

102 Downloads (Pure)

Abstract

Ticagrelor, a platelet P2Y 12 receptor antagonist, decreases thrombotic events in patients with coronary artery disease but increases the risk of bleeding. All antidote is not yet available. Platelet transfusion has the potential to reverse the antiplatelet effect cl ticagrelor and reduce bleeding. This thesis reports on an in vitro study which shows that donor platelets increase the aggregation of tlcagrelor-treated platelets. The extent of the increase is determined by the time since the previous dose of ticagrelor and the quantity of donor platelets. Using the in vitro results, estimates of the effect of platelet transfusion on platelet aggregation are made.

Original language	English
Qualification	Masters
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Eikelboom, John, Supervisor Linden, Matthew, Supervisor
Thesis sponsors	Australian Government Research Training Program
Award date	19 Dec 2019
DOIs	https://doi.org/10.26182/5e8a796c6e24c
Publication status	Unpublished - 2019

Access to Document

10.26182/5e8a796c6e24c

TH20 15 THESIS - MASTER OF CLINICAL RESEARCH - KRUGER Paul Christopher - 2020
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

Cite this

@mastersthesis{d2d1d613d3784551aaf88b6512057691,

title = "Reversal of the antiaggregant effect of ticagrelor in combination with acetylsalicylic acid, using normal platelets",

abstract = "Ticagrelor, a platelet P2Y 12 receptor antagonist, decreases thrombotic events in patients with coronary artery disease but increases the risk of bleeding. All antidote is not yet available. Platelet transfusion has the potential to reverse the antiplatelet effect cl ticagrelor and reduce bleeding. This thesis reports on an in vitro study which shows that donor platelets increase the aggregation of tlcagrelor-treated platelets. The extent of the increase is determined by the time since the previous dose of ticagrelor and the quantity of donor platelets. Using the in vitro results, estimates of the effect of platelet transfusion on platelet aggregation are made.",

keywords = "Anti-platelet, Ticagrelor, Aggregation, Bleeding, Platelet transfusion",

author = "Paul Kruger",

year = "2019",

doi = "10.26182/5e8a796c6e24c",

language = "English",

school = "The University of Western Australia",

}

TY - THES

T1 - Reversal of the antiaggregant effect of ticagrelor in combination with acetylsalicylic acid, using normal platelets

AU - Kruger, Paul

PY - 2019

Y1 - 2019

N2 - Ticagrelor, a platelet P2Y 12 receptor antagonist, decreases thrombotic events in patients with coronary artery disease but increases the risk of bleeding. All antidote is not yet available. Platelet transfusion has the potential to reverse the antiplatelet effect cl ticagrelor and reduce bleeding. This thesis reports on an in vitro study which shows that donor platelets increase the aggregation of tlcagrelor-treated platelets. The extent of the increase is determined by the time since the previous dose of ticagrelor and the quantity of donor platelets. Using the in vitro results, estimates of the effect of platelet transfusion on platelet aggregation are made.

AB - Ticagrelor, a platelet P2Y 12 receptor antagonist, decreases thrombotic events in patients with coronary artery disease but increases the risk of bleeding. All antidote is not yet available. Platelet transfusion has the potential to reverse the antiplatelet effect cl ticagrelor and reduce bleeding. This thesis reports on an in vitro study which shows that donor platelets increase the aggregation of tlcagrelor-treated platelets. The extent of the increase is determined by the time since the previous dose of ticagrelor and the quantity of donor platelets. Using the in vitro results, estimates of the effect of platelet transfusion on platelet aggregation are made.

KW - Anti-platelet

KW - Ticagrelor

KW - Aggregation

KW - Bleeding

KW - Platelet transfusion

U2 - 10.26182/5e8a796c6e24c

DO - 10.26182/5e8a796c6e24c

M3 - Master's Thesis

ER -

Reversal of the antiaggregant effect of ticagrelor in combination with acetylsalicylic acid, using normal platelets

Abstract

Access to Document

Fingerprint

Cite this